{"@context":{"@vocab":"https://schema.org/"},"@type":"Drug","@id":"https://api.morvs.ai/drug-product/68727-745#drug","name":"VYXEOS","alternateName":"(daunorubicin and cytarabine) liposome","identifier":[{"@type":"PropertyValue","propertyID":"FDA National Drug Code (NDC)","value":"68727-745"},{"@type":"PropertyValue","propertyID":"FDA application number","value":"NDA209401"},{"@type":"PropertyValue","propertyID":"UNII","value":"04079A1RDZ|ZS7284E0ZP"},{"@type":"PropertyValue","propertyID":"SPL Set ID","value":"7ea701ce-e7d3-4349-a9c2-642a501d45c8"}],"activeIngredient":"CYTARABINE, DAUNORUBICIN","administrationRoute":["INTRAVENOUS"],"dosageForm":"INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION","manufacturer":{"@type":"Organization","name":"Jazz Pharmaceuticals, Inc."},"drugClass":[],"isAvailableGenerically":false,"legalStatus":"HUMAN PRESCRIPTION DRUG","sameAs":["https://api.morvs.ai/drug-approval/NDA209401","https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ea701ce-e7d3-4349-a9c2-642a501d45c8","https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=68727-745"],"isAccessibleForFree":true,"license":"https://creativecommons.org/publicdomain/zero/1.0/","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://creativecommons.org/publicdomain/zero/1.0/","primary_source":"https://open.fda.gov/apis/drug/ndc/","generated_at":"2026-11-03T06:41:56.916Z"}}